Qura Therapeutics will develop HIV treatments in partnership with University of North Carolina at Chapel Hill, a venture in which it is investing $20m.
UK-based pharmaceutical company GlaxoSmithKline (GSK) has agreed to invest $20m in a partnership with University of North Carolina at the Chapel Hill (UNC-Chapel Hill) to find a cure for HIV.
The partnership includes the launch of an HIV Cure centre on the UNC-Chapel Hill campus and the formation of a jointly-owned company, Qura Therapeutics. The research centre, together with GSK, will look to attract partners and public funding, as well as experts from across the world.
A small group of…
